Top Stocks
Dividend Investing
Stock Comparison
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
Aquestive Therapeutics Stock Price & Analysis
1,583 Followers
AQST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $6.25
Previous Close$0.91
Volume83.15K
Average Volume (3M)569.02K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$18.65M
Total Debt (Recent Filing)$55.09M
Price to Earnings (P/E)-0.6
Beta1.95
Next EarningsMar 16, 2023
EPS Estimate-$0.25
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$4.83
EPS (TTM)-1.63
Shares Outstanding54,156,014
R-Squared0.23
Standard Deviation0.33
10 Day Avg. Volume189,099
30 Day Avg. Volume569,018
Price to Book (P/B)-0.44
Price to Sales (P/S)1.02
Price to Cash Flow (P/CF)38.20
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside415.86% Upside
Rating ConsensusStrong Buy
Alpha-0.03
Number of Analyst Covering6
Aquestive Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $0.62 and its highest was $6.25 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Currently, no data Available
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Mar 16, 2023 which is in 96 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Nov 01, 2022. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.059.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -$0.25.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 54,156,013 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Among the largest hedge funds holding Aquestive Therapeutics’s share is Caxton Associates LP. It holds Aquestive Therapeutics’s shares valued at N/A.
---
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.83
$4.83
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
---